STOCK TITAN
  1. Home
  2. SEC-Filings
  3. AVGR

Avinger Inc SEC Filings

AVGR NASDAQ

Welcome to our dedicated page for Avinger SEC filings (Ticker: AVGR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Avinger’s 10-K is packed with details on FDA clearances for Pantheris, revenue from Tigereye catheters, and the cash runway that keeps Lumivascular innovation moving forward. Whether you need to confirm trial milestones or monitor when executives sell shares before new device launches, Stock Titan curates every disclosure so you never miss a nuance.

Looking for an Avinger quarterly earnings report 10-Q filing or the latest Avinger insider trading Form 4 transactions? Our platform pulls each submission from EDGAR the moment it posts, then uses AI to deliver plain-English highlights, red-flag risk sections, and side-by-side trend charts. Skip the page-skimming and focus instead on what drives value—unit sales, gross margins, and R&D spend.

  • Avinger annual report 10-K simplified – deep dives into product revenue and FDA strategy
  • Avinger Form 4 insider transactions real-time – track every executive stock move
  • Avinger proxy statement executive compensation – see how pay aligns with clinical progress
  • Avinger 8-K material events explained – understand financing rounds, study data, or leadership changes

From “understanding Avinger SEC documents with AI” to fast Avinger earnings report filing analysis, Stock Titan turns dense text into actionable insight. Investors use it to compare sequential catheter sales, gauge cash burn against upcoming trials, and watch for Avinger executive stock transactions Form 4. All SEC filings explained simply, updated in real time, and ready for informed decision-making.

Filing

[25-NSE] Avinger, Inc. SEC Filing

Rhea-AI Summary
Avinger's common stock is being delisted from the Nasdaq Stock Market through a Form 25 filing on June 23, 2025. The delisting action is being executed by Nasdaq's Hearings Advisor Aravind Menon, indicating this may be the result of a hearing process. The filing complies with SEC Rule 240.12d2-2(b), confirming that Nasdaq has followed its internal rules for delisting. Avinger, headquartered in Redwood City, California, trades under Commission File Number 001-36817. This regulatory action represents a significant development for shareholders as it means the company's stock will no longer be traded on the Nasdaq exchange, potentially impacting liquidity and trading accessibility.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other

FAQ

What is the current stock price of Avinger (AVGR)?

The current stock price of Avinger (AVGR) is $0.474 as of April 29, 2025.

What is the market cap of Avinger (AVGR)?

The market cap of Avinger (AVGR) is approximately 1.8M.

What is Avinger Inc's primary business?

Avinger Inc develops image-guided, catheter-based systems for diagnosing and treating vascular diseases, including peripheral and coronary artery conditions.

What is the Lumivascular platform?

The Lumivascular platform is Avinger's proprietary technology that integrates OCT imaging with therapeutic catheters, allowing real-time visualization during vascular interventions.

Which vascular conditions do Avinger's products target?

Avinger's devices are primarily used for treating peripheral artery disease and managing complex conditions such as chronic total occlusions and coronary artery blockages.

How does Avinger's technology benefit physicians?

By providing high-resolution, real-time imaging inside the artery, physicians can accurately navigate devices, reduce reliance on traditional X-ray imaging, and achieve more predictable outcomes.

What makes Avinger's approach unique in the medical device market?

Avinger stands out with its exclusive focus on image-guided interventions, offering a technological edge through its integrated OCT system and specialized catheter designs that enhance procedural safety.

What products are included in Avinger's portfolio?

The portfolio includes the Lightbox imaging console, the Ocelot and Tigereye series of CTO catheters, and the Pantheris atherectomy devices designed for the treatment of PAD.

How does Avinger address the challenges of vascular interventions?

By employing a real-time, image-guided approach, Avinger improves device navigation and plaque removal, thereby streamlining complex procedures and enhancing clinical results.

In what ways does Avinger demonstrate industry expertise?

Avinger combines rigorous R&D, a strong patent portfolio, clinical collaborations, and strategic partnerships to reinforce its authority and trustworthiness in the field of vascular therapy.
Stock AVGR logo
Avinger Inc

NASDAQ:AVGR

AVGR Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

AVGR Stock Data

1.84M
3.05M
7.94%
10.16%
4.13%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
REDWOOD CITY